drugset
drugset / Trial / NCT00760396

Multiple-Dose Study of VGX-1027 in Healthy Subjects

NCT00760396 ↗

Phase 1 Completed 40 enrolled VGX Pharmaceuticals, LLC GeneOne Life Science, Inc. · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety profile, tolerability and pharmacokinetics following multiple oral doses of 40mg to 200mg VGX 1027 in healthy subjects administered for 5 days.

Timeline

Start
2008-09
Primary completion
2008-11
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject VGX-1027 Small molecule 40 mg Oral
Subject VGX-1027 Small molecule 100 mg Oral
Subject VGX-1027 Small molecule 200 mg Oral

Indications

No indication recorded.